ADR Therapeutics Initiates Joint Research on "Neocella" with Exosome Expert Prof. Takahiro Ochiya of Tokyo Medical University

Key facts

  • ADR Therapeutics Initiates Joint Research on "Neocella" with Exosome Expert Prof. Takahiro Ochiya of Tokyo Medical University
  • Source: PR Times
  • Date: May 15, 2026

Direct answer

ADR Therapeutics, a subsidiary of ADR120S, has entered into a joint research agreement with Tokyo Medical University to study "Neocella," a promising new extracellular vesicle platform. The research is led by Professor Takahiro Ochiya, a leading global authority in exosome research. The collaboration aims to evaluate Neocella's biological functions, clarify its mechanisms, explore its application in animal inflammatory diseases like endometritis, and establish a stable manufacturing process for

Citation
ADR Therapeutics Initiates Joint Research on "Neocella" with Exosome Expert Prof. Takahiro Ochiya of Tokyo Medical University (May 15, 2026), PR Times
Source
PR Times
Date
May 15, 2026
出典：PR Times

📋 Article Processing Timeline

  • 📰 Published: May 15, 2026 at 17:32
  • 🔍 Collected: May 15, 2026 at 09:02
  • 🤖 AI Analyzed: May 15, 2026 at 11:02 (2h 0m after Collected)
ADR Therapeutics, a subsidiary of ADR120S, has entered into a joint research agreement with Tokyo Medical University to study "Neocella," a promising new extracellular vesicle platform. The research is led by Professor Takahiro Ochiya, a leading global authority in exosome research. The collaboration aims to evaluate Neocella's biological functions, clarify its mechanisms, explore its application in animal inflammatory diseases like endometritis, and establish a stable manufacturing process for future practical use.

FAQ

What are the key facts in this article?

ADR Therapeutics, a subsidiary of ADR120S, has entered into a joint research agreement with Tokyo Medical University to study "Neocella," a promising new extracellular vesicle platform. The research is led by Professor Takahiro Ochiya, a leading global authority in exosome research. The collaboration aims to evaluate Neocella's biological functions, clarify its mechanisms, explore its application in animal inflammatory diseases like endometritis, and establish a stable manufacturing process for

What is the direct answer?

ADR Therapeutics, a subsidiary of ADR120S, has entered into a joint research agreement with Tokyo Medical University to study "Neocella," a promising new extracellular vesicle platform. The research is led by Professor Takahiro Ochiya, a leading global authority in exosome research. The collaboration aims to evaluate Neocella's biological functions, clarify its mechanisms, explore its application in animal inflammatory diseases like endometritis, and establish a stable manufacturing process for

What is the source and date?

PR Times: https://prtimes.jp/main/html/rd/p/000000012.000072610.html | May 15, 2026

Back to Newsroom (28)